Chen, B.;                     Yang, S.;                     Zhu, L.;                     Peng, X.;                     He, D.;                     Tao, T.;                     Su, W.    
        Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis. J. Clin. Med. 2022, 11, 6686.
    https://doi.org/10.3390/jcm11226686
    AMA Style
    
                                Chen B,                                 Yang S,                                 Zhu L,                                 Peng X,                                 He D,                                 Tao T,                                 Su W.        
                Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis. Journal of Clinical Medicine. 2022; 11(22):6686.
        https://doi.org/10.3390/jcm11226686
    
    Chicago/Turabian Style
    
                                Chen, Binyao,                                 Shizhao Yang,                                 Lei Zhu,                                 Xuening Peng,                                 Daquan He,                                 Tianyu Tao,                                 and Wenru Su.        
                2022. "Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis" Journal of Clinical Medicine 11, no. 22: 6686.
        https://doi.org/10.3390/jcm11226686
    
    APA Style
    
                                Chen, B.,                                 Yang, S.,                                 Zhu, L.,                                 Peng, X.,                                 He, D.,                                 Tao, T.,                                 & Su, W.        
        
        (2022). Adalimumab plus Conventional Therapy versus Conventional Therapy in Refractory Non-Infectious Scleritis. Journal of Clinical Medicine, 11(22), 6686.
        https://doi.org/10.3390/jcm11226686